Pacira BioSciences, Inc. (PCRX) financial statements and ratios from SEC XBRL: revenue $0.7B (TTM), net margin 1.0%, revenue growth 6.2% YoY, P/E 67.2. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $726.41M |
| Revenue (TTM) | $0.7B |
| Net Margin | 1.0% |
| Operating Margin (TTM) | 2.7% |
| Net Debt / EBITDA | 1.5 |
| Revenue Growth (YoY) | 6.2% |
| EPS Growth (YoY) | -209.1% |
| FCF Growth (YoY) | 502.5% |
| P/E Ratio | 67.2 |
| EV / EBITDA | 10.9 |
| Price / Book | 1.46 |
| Price / Sales | 1.32 |
| FCF Yield | 18.3% |
| Altman Z-Score | 1.86 (grey) |
| Piotroski F-Score | 9/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
PCRX overview · PCRX earnings · PCRX KPIs · PCRX documents · PCRX ownership · PCRX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.